Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation.
Conclusion Low fixed dose defibrotide initiated early seems to be effective and safe in treatment of VOD. This is relevant in a resource limited setting and warrants prospective evaluation.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
More News: Bleeding | Cancer & Oncology | Children | Dialysis | Furosemide | Hematology | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants